Compare DUO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6M | 19.9M |
| IPO Year | 2018 | 2023 |
| Metric | DUO | CMMB |
|---|---|---|
| Price | $0.58 | $2.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.3M | 98.7K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $68.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.35 |
| 52 Week High | $5.34 | $3.55 |
| Indicator | DUO | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 81.92 |
| Support Level | $0.58 | $1.47 |
| Resistance Level | $0.70 | $2.80 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 0.11 | 77.42 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.